Starpharmaの簿価
Starpharmaの簿価 は何ですか。
Starpharma Holdings Limitedの簿価 は0.01です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
ASXのセクタHealth Careにおける簿価 の企業と比べるStarpharma
Starpharmaは何をしますか。
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharmaと類似の簿価
- Mundoro Capitalの簿価 は0.01です。
- Renavotio Incの簿価 は0.01です。
- Novan Incの簿価 は0.01です。
- Babylon Pump & Powerの簿価 は0.01です。
- Kitov Pharma Ltdの簿価 は0.01です。
- Atari SAの簿価 は0.01です。
- Starpharmaの簿価 は0.01です。
- Bold Venturesの簿価 は0.01です。
- International Business Settlementの簿価 は0.01です。
- 4DS Memoryの簿価 は0.01です。
- Rover Metalsの簿価 は0.01です。
- Vitality Biopharmaの簿価 は0.01です。
- Galore Resourcesの簿価 は0.01です。